MRK – merck & company, inc. (new) (US:NASDAQ)
Stock Stats
News
11/14
07:26 am
mrk
Low
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen [Yahoo! Finance]
11/14
07:15 am
mrk
Low
Merck to Participate in the Jefferies London Healthcare Conference
11/14
06:59 am
mrk
Low
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. [Yahoo! Finance]
11/14
06:45 am
mrk
Low
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
11/13
05:05 pm
mrk
Low
Kimberly-Clark Elects Joseph Romanelli to its Board of Directors [Yahoo! Finance]
10/31/2024
06:30 am
mrk
-3.4%
BEAT
7/30/2024
06:30 am
mrk
-10.9%
BEAT
4/25/2024
06:30 am
mrk
2.5%
BEAT
2/1/2024
06:30 am
mrk
4.7%
BEAT
11/11
08:08 am
Downgrades
Buy
Neutral
Daiwa Capital Markets
Low
-2.0%
11/6
01:11 pm
Maintains
Buy
Buy
Guggenheim
Low
-0.7%
11/6
01:11 pm
Maintains
Buy
Buy
Guggenheim
Low
-0.7%
11/1
02:44 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
-0.3%
11/1
02:44 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
-0.3%
11/6
04:06 pm
mrk
Low
Form 10-Q Merck & Co., Inc. For: Sep 30
11/4
10:06 am
mrk
Low
Form 25-NSE Merck & Co., Inc. Filed by: NEW YORK STOCK EXCHANGE LLC
10/31
06:44 am
mrk
Medium
Form 8-K Merck & Co., Inc. For: Oct 31
10/1
02:16 pm
mrk
Low
Form 4 Merck & Co., Inc. For: Sep 30 Filed by: Seidman Christine E
10/1
02:11 pm
mrk
Low
Form 4 Merck & Co., Inc. For: Sep 30 Filed by: GLOCER THOMAS H
Show more
Top News Gainers
3/28 Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies 7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
Top News Decliners
3/13 Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily] -8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3